CD163 and glioblastoma: To be more specific, GBM patients with a high expression of CD163 had a poor overall survival (Figure 4(a), p = 0.0437, HR (95%CI) = 1.45(1.01 − 2.09)), prognosis-free survival (Figure 4(b), p = 0.012, HR (95%CI) = 1.60(1.11 − 2.30)), and disease-specific survival (Figure 4(c), p = 0.048, HR (95%CI) = 1.48(1.00 − 2.17)) with a 3-year AUC of 0.744 (Figure 4(a)), 0.63 (Figure 4(b)), and 0.749 (Figure 4(c)), respectively.